MARKET

LHDX

LHDX

Lucira Health, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.02
-0.01
-0.20%
Closed 17:41 06/22 EDT
OPEN
5.04
PREV CLOSE
5.03
HIGH
5.20
LOW
4.910
VOLUME
359.18K
TURNOVER
--
52 WEEK HIGH
37.99
52 WEEK LOW
4.230
MARKET CAP
180.05M
P/E (TTM)
-4.9683
1D
5D
1M
3M
1Y
5Y
Healthcare names dominate premarket gainers
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor
Seekingalpha · 06/11 12:28
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27)
Benzinga · 05/28 12:02
Lucira Health appoints medtech veteran Kevin Collins as CRO
Lucira Health (LHDX) announces Kevin Collins has joined the company as chief revenue officer with global revenue responsibility.Most recently, he was Vice President of International Commercial Operations at Outset Medical
Seekingalpha · 05/28 10:06
LUCIRA(TM) HEALTH Hires Chief Revenue Officer Kevin Collins
Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced medtech veteran Kevin Collins has joined the company as Chief R...
Business Wire · 05/28 10:00
Lucira Health to Participate in William Blair 41st Annual Growth Stock Conference
EMERYVILLE, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test ki...
GlobeNewswire · 05/25 11:00
52 Biggest Movers From Yesterday
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive immuno-oncology RNA therapy for the treatment of multiple cancer...
Benzinga · 05/25 08:56
35 Stocks Moving In Monday's Mid-Day Session
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares jumped 123.7% to $13.33 after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.
Benzinga · 05/24 16:09
Thinking about buying stock in Marrone Bio Innovations, Village Farms, Moxian, Lucira Health, or Kadmon Holdings?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MBII, VFF, MOXC, LHDX, and KDMN.
PR Newswire - PRF · 05/21 13:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LHDX. Analyze the recent business situations of Lucira Health, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LHDX stock price target is 8.50 with a high estimate of 9.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 19.29M
% Owned: 53.77%
Shares Outstanding: 35.87M
TypeInstitutionsShares
Increased
0
0
New
50
19.29M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About LHDX
Lucira Health, Inc. is medical technology company. The Company is focused on the development and commercialization of transformative and infectious disease test kits. The Company has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and test kit that is powered by two AA batteries and fit in the palm of a hand. Its initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications. It has developed LUCIRA COVID-19 All-In-One Test Kit (COVID-19 test kit), is a single-use, molecular in vitro diagnostic test that has an analytical sensitivity to detect the SARS-CoV-2 virus. The test is authorized for prescription at-home use.

Webull offers kinds of Lucira Health Inc stock information, including NASDAQ:LHDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LHDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LHDX stock methods without spending real money on the virtual paper trading platform.